Vasopressin as a Hemostatic in Gynecologic Surgery

Dillon, Thomas F.; Marbury, Benjamin E.; Bonsnes, Roy W.; Douglas, R G; DuVigneaud, Vincent

doi:10.1097/00006254-195813000-00046

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enter the case report by Hobo et al (see p. 484), an article of significant clinical relevance to gynecologic surgeons. 9 Based on reports of cardiovascular complications with total doses of 10 to 15 units, they arbitrarily chose to use 4 units as the total maximum dose diluted in 20 mL of saline (0.2 U/mL). Well-designed studies have shown it to decrease blood loss significantly during abdominal hysterectomy 2 and myomectomy by abdominal 3 or hysteroscopic 4 approach.…”

Section: Vasopressinmentioning

confidence: 99%

Vasopressin

Frishman¹

2009

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Section: Vasopressinmentioning

confidence: 99%

Vasopressin

Frishman¹

2009

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

“…However, synthetic vasopressin is not available in some parts of the world including China. Pituitrin, a bovine posterior pituitary extract containing OPEN ACCESS EDITED BY vasopressin and oxytocin, has been considered as a well-accepted alternative to vasopressin during myomectomy owing to its similar clinical effect as that of synthetic vasopressin and its lower price (3)(4)(5). However, pituitrin can cause drastic fluctuations in hemodynamics, including significantly increasing blood pressure, and slowing the heart rate, which can induce cardiovascular and cerebrovascular events (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Dose–response study of prophylactic nitroglycerin for prevention of pituitrin-induced hypertension during laparoscopic myomectomy: a prospective, randomized study

Wang

Xiao

et al. 2023

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo determine the dose–response of nitroglycerin in preventing pituitrin-induced hypertension in patients undergoing laparoscopic myomectomy.MethodsHundred patients scheduled for elective laparoscopic myomectomy were randomly allocated into one of five groups (n = 20) to receive intravenous bolus of prophylactic nitroglycerin at 0, 50, 75, 100, and 125 μg one minute following administration of 3 IU of pituitrin into the myometrium. The patients were monitored for pituitrin-induced hypertension with the primary outcome to determine the effective dose of prophylactic nitroglycerin, defined as complete prevention of pituitrin-induced hypertension during the study period. Probit analysis was used to calculate the median effective dose (ED50) and 95% effective dose (ED95) of prophylactic nitroglycerin.ResultsHypertension occurred in 19/20, 10/20, 8/20, 2/20, and 1/20 in patients who received 0, 50, 75, 100, and 125 ug of prophylactic nitroglycerin, respectively. The calculated ED50 and ED95 of nitroglycerin for preventing hypertension were 54 μg (95%CI: 35~66 μg) and 136 μg (95%CI: 105~289 μg).ConclusionA prophylactic bolus of nitroglycerin administered immediately following injection of pituitrin into the myometrium during laparoscopic myomectomy effectively prevented pituitrin-induced hypertension, with the ED50 and ED95 of 54 μg and 136 μg, respectively. This information would be useful for clinical practice.Clinical trial registrationwww.chictr.org.cn, Identifier ChiCTR2200062282.

show abstract

“…[123] The systemic effects of vasopressin pose significant challenges for the anesthesiologist as it may cause bradycardia, hypotension and fatal cardiac complications such as arrhythmias and cardiac arrest. [456] We report a case of intramyometrial injection of vasopressin and further discuss adverse effects and complications related to it.…”

mentioning

confidence: 99%